Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

CorMedix (CRMD) Payables (2016 - 2025)

CorMedix has reported Payables over the past 15 years, most recently at $7.9 million for Q4 2025.

  • Quarterly results put Payables at $7.9 million for Q4 2025, up 358.37% from a year ago — trailing twelve months through Dec 2025 was $7.9 million (up 358.37% YoY), and the annual figure for FY2025 was $7.9 million, up 358.37%.
  • Payables reached $7.9 million in Q4 2025 per CRMD's latest filing, down from $20.5 million in the prior quarter.
  • Across five years, Payables topped out at $20.5 million in Q3 2025 and bottomed at $943344.0 in Q2 2021.
  • Median Payables over the past 5 years was $2.2 million (2021), compared with a mean of $3.5 million.
  • The largest annual shift saw Payables plummeted 60.69% in 2021 before it skyrocketed 1422.09% in 2025.
  • Over 5 years, Payables stood at $2.2 million in 2021, then decreased by 0.34% to $2.2 million in 2022, then surged by 94.34% to $4.3 million in 2023, then tumbled by 59.81% to $1.7 million in 2024, then surged by 358.37% to $7.9 million in 2025.
  • Business Quant data shows Payables for CRMD at $7.9 million in Q4 2025, $20.5 million in Q3 2025, and $5.8 million in Q2 2025.